Qualigen Therapeutics Files 8-K with Material Agreements
Ticker: AIXC · Form: 8-K · Filed: Oct 3, 2025 · CIK: 1460702
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
Related Tickers: QLGN
TL;DR
Qualigen Therapeutics (QLGN) filed an 8-K on 9/29/25 detailing material agreements and equity sales.
AI Summary
On September 29, 2025, Qualigen Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. This filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions, including material definitive agreements and equity sales, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- September 29, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-37428 (file_number) — SEC File Number
- 26-3474527 (ein) — IRS Employer Identification No.
- 5857 Owens Avenue , Suite 300 , Carlsbad , California 92008 (address) — Address of principal executive offices
FAQ
What specific material definitive agreement was entered into by Qualigen Therapeutics, Inc. on September 29, 2025?
The filing states that Qualigen Therapeutics, Inc. entered into a material definitive agreement on September 29, 2025, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold in the unregistered sales reported by Qualigen Therapeutics?
The filing mentions unregistered sales of equity securities, but the specific type and details of these securities are not detailed in the provided text.
What are the key financial statements and exhibits included in this 8-K filing?
The filing indicates that financial statements and exhibits are included, but the specific content of these documents is not detailed in the provided text.
What is the principal executive office address for Qualigen Therapeutics, Inc.?
The principal executive office address for Qualigen Therapeutics, Inc. is 5857 Owens Avenue, Suite 300, Carlsbad, California 92008.
What is the SEC File Number for Qualigen Therapeutics, Inc.?
The SEC File Number for Qualigen Therapeutics, Inc. is 001-37428.
Filing Stats: 2,572 words · 10 min read · ~9 pages · Grade level 14.6 · Accepted 2025-10-03 17:27:31
Key Financial Figures
- $0.001 — ch registered Common stock (par value $0.001 per share) QLGN The Nasdaq Stock Ma
- $41,000,000 — which the investors agreed to purchase $41,000,000 in cash (the "Offering") including 337,
- $2.246 — purchase price of the Common Stock was $2.246 per share and the purchase price for th
- $1,000 — rchase price for the Series B Stock was $1,000 per share (the "Stated Value"). At the
- $6,800,000 — p"). The Company intends to use up to $6,800,000 of the net cash proceeds from the Offer
- $2.47 — cise price per share of Common Stock of $2.47 (the "Placement Agent Warrants"). In ad
- $150,000 — reimburse the Placement Agent for up to $150,000 of its fees and expenses. The issuanc
Filing Documents
- form8-k.htm (8-K) — 65KB
- ex99-1.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 14KB
- 0001493152-25-016923.txt ( ) — 273KB
- qlgn-20250929.xsd (EX-101.SCH) — 3KB
- qlgn-20250929_lab.xml (EX-101.LAB) — 33KB
- qlgn-20250929_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: October 3, 2025 By: /s/ Kevin A. Richardson II Kevin A. Richardson II Co-Chief Executive Officer